Shopping Cart
- Remove All
- Your shopping cart is currently empty
Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to the inhibition of the growth of malignant B-cells that overexpress BTK.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 1-2 weeks |
Description | Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This |
Alias | RG-7845, RG7845, RG 7845, GDC-0853, GDC0853, GDC 0853 |
Molecular Weight | 701.27 |
Formula | C37H45ClN8O4 |
Cas No. | 2128304-54-9 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.